# Longwood Fund

> Longwood Fund is a VC fund in Boston backing Biotechnology and Therapeutics. See 77 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 77
- Last investment: Apr 2026
- Lead investor: 16%
- Last fund: May 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/longwoodfund/
- X (Twitter): https://twitter.com/longwoodfund
- Website: http://www.longwoodfund.com

Longwood Fund is a VC fund in Boston focused on Biotechnology and Therapeutics. Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

## Contacts

5 contacts available for Longwood Fund. Shizune tracks 7 team members at Longwood Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/longwood-founders-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $16M–$100M |
| Series B | $25M–$152M |
| Series C | $17M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 38 | 49% |
| Therapeutics | 19 | 25% |
| Health Care | 18 | 23% |
| Life Science | 16 | 21% |
| Pharmaceutical | 13 | 17% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 26 | 34% |
| Series B | 16 | 21% |
| Series C | 9 | 12% |
| Funding Round | 6 | 8% |
| Seed | 1 | 1% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 51% |
| United Kingdom | 3 | 4% |
| Italy | 1 | 1% |
| Belgium | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aleks Radovic-Moreno | Partner | 1 | https://shizune.co/investors/profile/aleks-radovic-moreno |
| John McCabe | Operating Partner | 0 | https://shizune.co/investors/profile/john-mccabe-d84c |
| Christoph Westphal | Manager | 11 | https://shizune.co/investors/profile/christoph-westphal |
| David Donabedian | Executive Partner | 2 | https://shizune.co/investors/profile/david-donabedian |
| David Donabedian, PhD | Venture Partner | 1 | https://shizune.co/investors/profile/david-h-donabedian |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Neomorph | Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M | Series B | Apr 13, 2026 |  |
| Sidewinder Therapeutics | Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M | Series B | Apr 08, 2026 |  |
| Mediar Therapeutics | Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M | Series B | Jan 07, 2026 |  |
| AAVantgarde Bio | AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M | Series B | Nov 03, 2025 |  |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M | Series A | Sep 30, 2025 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M | Series B | Sep 04, 2025 |  |
| Solu Therapeutics | Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $41M | Series A | Apr 09, 2025 |  |
| Newleos Therapeutics | Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M | Series A | Feb 13, 2025 |  |
| Newleos Therapeutics | Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M | Series A | Feb 13, 2025 |  |

10 of 77 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 14 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 11 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 11 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 11 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 10 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 10 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)
- [Biotech Investors in Italy](https://shizune.co/investors/biotech-investors-italy)
- [Biotech VC Funds in Italy](https://shizune.co/investors/biotech-vc-funds-italy)

## FAQ

### What does Longwood Fund invest in?

Longwood Fund invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 77 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Longwood Fund's check size?

Longwood Fund typically joins rounds of $16M–$100M at Series A, $25M–$152M at Series B and $17M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longwood Fund participates in.

### How do I contact Longwood Fund?

Public channels for Longwood Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Longwood Fund?

The team at Longwood Fund includes Aleks Radovic-Moreno (Partner), John McCabe (Operating Partner) and Christoph Westphal (Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co